

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 February 2025 (27.02.2025)



(10) International Publication Number
WO 2025/040810 A1

(51) International Patent Classification:

A61P 15/00 (2006.01) C07D 493/22 (2006.01)
A61P 15/10 (2006.01) A61K 31/366 (2006.01)

(21) International Application Number:

PCT/EP2024/073743

(22) International Filing Date:

23 August 2024 (23.08.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/578,251 23 August 2023 (23.08.2023) US
63/571,339 28 March 2024 (28.03.2024) US

(71) Applicant: DICOT PHARMA AB [SE/SE]; St Olofsgatan
11A, 753 21 Uppsala (SE).


(72) Inventors: DOWNING, Kristie; 60872 Jasmine Pl., Bend,
Oregon 97702 (US). BOUCK, Heather; 2723 SW Volcano
Ct., Redmond, Oregon 97756 (US). KUMAR, Sandeep;
26 Long Lane, Oxford OX4 3TW (GB). WESTMAN, Ja-
cob; Jonsund Blomsberg 109, 74497 Järlåsa (SE). MALM-
BERG, Catarina; Ripgränd 6, 75653 Uppsala (SE).

(74) Agent: TOTTIE, Louise; Potter Clarkson AB, Riddargatan
10, 114 35 Stockholm (SE).


(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: THERAPEUTIC COMPOUNDS, A METHOD OF MANUFACTURING THEREOF AS WELL AS USES THEREOF




Formula Ib



Formula IIb

(57) Abstract: The disclosure provides a compound of Formula Ib or
Formula IIb, or a hydrate thereof, a pharmaceutical composition such as
a spray-dried pharmaceutical composition comprising the compound of
Formula Ib or Formula IIb, or a hydrate thereof, as well as methods of
preparation thereof, and use thereof in the treatment and/or prevention
of one or more of the following dysfunctions or disorders: a sexual
dysfunction, erectile dysfunction, ejaculatory dysfunction, hypoactive
sexual desire disorder, psychiatric disorder, neurological disorder.



Formula V1
Fig. 1D

WO 2025/040810 A1

[Continued on next page]

Declarations under Rule 4.17:

- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*